Paper25916698
Concurrent inhibition of MYC and BCL2 is a potentially effective treatment strategy for double hit and triple hit B-cell lymphomas.
Cinar M and 8 others. Leuk Res, 2015. Cited by 26 papers, by iCite.
Cite this record
ConductScience Library. Concurrent inhibition of MYC and BCL2 is a potentially effective treatment strategy for double hit and triple hit B-cell lymphomas. Papers, record 25916698. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/25916698
- Cell line
- CS-THL12 papers
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Concurrent inhibition of MYC and BCL2 is a potentially effective treatment strategy for double hit and triple hit B-cell lymphomas.
- PubMed
Connected records1
Records in the library's other databases whose lists name this one, each read from that database's own release: up to 20 of each kind, the most connected first.
Cell lines1
Source Cell lines
Topics6
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Genes, myc | Major topic |
| Lymphoma, B-Cell | Major topic |
| Proto-Oncogene Proteins c-bcl-2 | Major topic |
| Bridged Bicyclo Compounds, Heterocyclic | |
| Humans | |
| Sulfonamides |
Source PubMed
Cited by18
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 26 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 41681925 | The Phase Ib VenObi CNS Study: Chemotherapy-Free Treatment with Venetoclax and Obinutuzumab for Relapsed/Refractory Primary Large B-Cell Lymphoma of the Central Nervous System. | Cancers (Basel) | 2026 | https://conductscience.org/library/papers/41681925 | PubMed |
| 40569497 | Elevated oncogene expressions in koala infected with multiple koala retrovirus subtypes: a preliminary study. | Virus Genes | 2025 | https://conductscience.org/library/papers/40569497 | PubMed |
| 37924446 | C-Myc inhibition intensified the anti-leukemic properties of Imatinib in chronic myeloid leukemia cells. | Mol Biol Rep | 2023 | https://conductscience.org/library/papers/37924446 | PubMed |
| 37457123 | Targeting MYC-driven lymphoma: lessons learned and future directions. | Cancer Drug Resist | 2023 | https://conductscience.org/library/papers/37457123 | PubMed |
| 35687491 | Genetic characterization and drug sensitivity study of newly derived HGBL double/triple-hit lymphoma cell lines. | Blood Adv | 2022 | https://conductscience.org/library/papers/35687491 | PubMed |
| 35482553 | Targeting MYC and BCL2 by a natural compound for "double-hit" lymphoma. | Hematol Oncol | 2022 | https://conductscience.org/library/papers/35482553 | PubMed |
| 33777762 | CS2164 and Venetoclax Show Synergistic Antitumoral Activities in High Grade B-Cell Lymphomas With MYC and BCL2 Rearrangements. | Front Oncol | 2021 | https://conductscience.org/library/papers/33777762 | PubMed |
| 32165486 | The HDAC and PI3K dual inhibitor CUDC-907 synergistically enhances the antileukemic activity of venetoclax in preclinical models of acute myeloid leukemia. | Haematologica | 2021 | https://conductscience.org/library/papers/32165486 | PubMed |
| 30523053 | Targeting BCL2 with venetoclax is a promising therapeutic strategy for "double-proteinexpression" lymphoma with MYC and BCL2 rearrangements. | Haematologica | 2019 | https://conductscience.org/library/papers/30523053 | PubMed |
| 30076412 | Tumor penetrating peptides inhibiting MYC as a potent targeted therapeutic strategy for triple-negative breast cancers. | Oncogene | 2019 | https://conductscience.org/library/papers/30076412 | PubMed |
| 29931583 | Dual targeting of bromodomain-containing 4 by AZD5153 and BCL2 by AZD4320 against B-cell lymphomas concomitantly overexpressing c-MYC and BCL2. | Invest New Drugs | 2019 | https://conductscience.org/library/papers/29931583 | PubMed |
| 29151814 | De novo acute lymphoblastic leukemia-like disease of high grade B-cell lymphoma with MYC and BCL2 and/or BCL6 rearrangements: a case report and literature review. | BMC Clin Pathol | 2017 | https://conductscience.org/library/papers/29151814 | PubMed |
| 29146569 | Found in Translation: How Preclinical Research Is Guiding the Clinical Development of the BCL2-Selective Inhibitor Venetoclax. | Cancer Discov | 2017 | https://conductscience.org/library/papers/29146569 | PubMed |
| 28377453 | Combination Therapy Targeting BCL6 and Phospho-STAT3 Defeats Intratumor Heterogeneity in a Subset of Non-Small Cell Lung Cancers. | Cancer Res | 2017 | https://conductscience.org/library/papers/28377453 | PubMed |
| 28074072 | Targeting BET proteins improves the therapeutic efficacy of BCL-2 inhibition in T-cell acute lymphoblastic leukemia. | Leukemia | 2017 | https://conductscience.org/library/papers/28074072 | PubMed |
| 27980306 | Treatment of Diffuse Large B-Cell Lymphoma. | J Clin Exp Hematop | 2016 | https://conductscience.org/library/papers/27980306 | PubMed |
| 27419806 | Therapeutic implication of concomitant chromosomal aberrations in patients with aggressive B-cell lymphomas. | Cell Cycle | 2016 | https://conductscience.org/library/papers/27419806 | PubMed |
| 27231235 | Farnesiferol c induces apoptosis via regulation of L11 and c-Myc with combinational potential with anticancer drugs in non-small-cell lung cancers. | Sci Rep | 2016 | https://conductscience.org/library/papers/27231235 | PubMed |
Genes3
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes | Source |
|---|---|---|---|---|
| BCL2 | 596 | PubTator's text mining | https://conductscience.org/library/genes/596 | NCBI Gene |
| BCL6 | 604 | PubTator's text mining | https://conductscience.org/library/genes/604 | NCBI Gene |
| MYC | 4609 | PubTator's text mining | https://conductscience.org/library/genes/4609 | NCBI Gene |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- References
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/25916698
GET https://conductscience.org/api/papers/v1/25916698/authors